Amlodipine besylate and benazepril hydrochloride capsules is a combination of amlodipine besylate and benazepril hydrochloride. Benazeprilat, the active metabolite of benazepril, is a nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Benazepril is converted to benazeprilat by hepatic cleavage of the ester group. Amlodipine besylate is the besylate salt of amlodipine, a dihydropyridine calcium channel blocker. Amlodipine besylate and benazepril hydrochloride capsules are formulated in four different strengths for oral administration with a combination of amlodipine besylate equivalent to 2.5 mg, 5 mg or 10 mg of amlodipine, with 10 mg or 20 mg of benazepril hydrochloride providing for the following available combinations: 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg.
Amlodipine besylate and benazepril hydrochloride capsules is a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension (1) in patients not adequately controlled on monotherapy with either agent
Media Articles Related to Amlobenz (Amlodipine / Benazepril)
Breast cancer treatments could increase risk of developing osteoporosis or hypertension
Source: Health News from Medical News Today [2014.02.28]
Older women who have overcome breast cancer are likely to struggle with heart disease, osteoporosis and hypertension further on in their lives. Whether these conditions occur or not is influenced by the treatment that patients received to fight cancer, their overall weight and their age. Breast cancer survivors therefore should watch their weight and get regular exercise so that they can enjoy a high quality of life. These findings, by lead author Nadia Obi of the University Medical Center Hamburg-Eppendorf, who collaborated with the group of Prof.
10 of 11 new gene signals are likely drug targets for hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2014.02.24]
A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.
Opsumit approved by SwissMedic for pulmonary arterial hypertension
Source: Hypertension News From Medical News Today [2014.02.17]
Actelion Ltd has announced that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality.
Air pollution increases risk for hypertension in pregnant women
Source: Hypertension News From Medical News Today [2014.02.14]
Breathing the air outside their homes may be just as toxic to pregnant women - if not more so - as breathing in cigarette smoke, increasing a mom-to-be's risk of developing deadly complications such as preeclampsia, according to findings from a new University of Florida study.
How the body regulates neuro-hormone has implications for hypertension, pain, stress, depression
Source: Anxiety / Stress News From Medical News Today [2014.02.12]
New research has revealed a previously unknown mechanism in the body which regulates a hormone that is crucial for motivation, stress responses and control of blood pressure, pain and appetite. The breakthrough could be used to design drugs to help fight health problems connected with these functions in the future.
Published Studies Related to Amlobenz (Amlodipine / Benazepril)
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. [2010.06]
This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)... We conclude that titration of amlodipine and benazepril in single-pill combinations is more effective than titration of amlodipine alone for rapid BP control in patients with severe hypertension.
An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension. [2008.06]
CONCLUSIONS: In this group of patients, comparable antihypertensive effects were seen with the fixed-dose combination therapy, compared with amlodipine monotherapy. Both treatments appeared well tolerated in the studied population, but cough was more common in the fixed-dose combination group.
The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. [2007.03]
BACKGROUND: This study compared the efficacy and safety of amlodipine/benazepril (10/40 mg/day and 10/20 mg/day) with amlodipine 10 mg/day in patients whose blood pressure (BP) was not adequately controlled with amlodipine monotherapy... CONCLUSION: Amlodipine/benazepril combinations were well tolerated and resulted in significant BP reductions and better BP responder rates than amlodipine monotherapy.
Comparative efficacy and safety of amlodipine/benazepril combination therapy and
amlodipine monotherapy in severe hypertension. 
This multicentre, double-blind, trial in subjects with severe hypertension
compared the efficacy and tolerability of two parallel drug regimens: A/B
(amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine:
5 or 10 mg daily, if necessary)... We conclude that titration of amlodipine and benazepril
in single-pill combinations is more effective than titration of amlodipine alone
for rapid BP control in patients with severe hypertension.
Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. 
BACKGROUND: Treatment regimens that require fewer dosage units and less frequent dosing to decrease the complexity and cost of care are among the strategies recommended to improve compliance with antihypertensive therapy. Simplifying therapy may be particularly important for elderly patients, who are more likely to have co-morbid conditions and to be taking multiple medications. OBJECTIVE: To determine rates of compliance with antihypertensive therapy and total costs of care among elderly Medicaid recipients treated with fixed-dose combination amlodipine besylate/benazepril versus a dihydropyridine calcium channel antagonist and ACE inhibitor prescribed as separate agents (free combination)... CONCLUSION: Use of fixed-dose amlodipine besylate/benazepril HCl by elderly Medicaid recipients was associated with improved compliance and lower healthcare costs compared with a dihydropyridine calcium channel antagonist and ACE inhibitor prescribed as separate agents.
Clinical Trials Related to Amlobenz (Amlodipine / Benazepril)
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension [Completed]
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult
Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure
is not adequately controlled with benazepril monotherapy during a 4 week run-in period will
be randomly allocated to double blind treatment over 8 weeks with either a combination of
benazepril/hydrochlorothiazide per day or continuation of benazepril per day.
Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients [Recruiting]
Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency [Recruiting]
The primary aim of the present study is to assess the safety of combined treatment of
benazepril (an ACE inhibitor) or losartan (an ARB) in non-diabetic patients with advanced
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) [Active, not recruiting]
The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is
superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive
subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors [Recruiting]
RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help
lower blood pressure.
PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril,
ramipril, or losartan potassium works in treating hypertension in patients with solid